{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:39:37Z","timestamp":1792111177861,"version":"4.4.0"},"reference-count":85,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hemophilia is the most common of the severe bleeding disorders and if not properly managed since early infancy can lead to chronic disease and lifelong disabilities. However, it enjoys the most efficacious and safe treatment among the most prevalent monogenic disorders. Hemophilia should be considered in the neonatal period in the case of unusual bleeding or in the case of positive family history. Later, hemophilia should be suspected mainly in males because of abnormal bruising\/bleeding or unusual bleeding following invasive procedures\u2014for example, tonsillectomy or circumcision. Prophylactic treatment that is started early with clotting-factor concentrates has been shown to prevent hemophilic arthropathy and is, therefore, the gold standard of care for hemophilia A and B in most countries with adequate resources. Central venous access catheters and arterovenous fistulas play an important role in the management of hemophilia children requiring repeated and\/or urgent administration of coagulation factor concentrates. During childhood and adolescence, personalized treatment strategies that suit the patient and his lifestyle are essential to ensure optimal outcomes. Physical activity is important and can contribute to better coordination, endurance, flexibility and strength. The present article focuses also on questions frequently posed to pediatric hematologists like vaccinations, day-care\/school access and dental care.<\/jats:p>","DOI":"10.3390\/jcm6050054","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T01:47:33Z","timestamp":1495504053000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Hemophilia Care in the Pediatric Age"],"prefix":"10.3390","volume":"6","author":[{"given":"Marta","family":"Bertamino","sequence":"first","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Children\u2019s Hospital, 16147 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Giannina Gaslini Children\u2019s Hospital, 16147 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Banov","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Children\u2019s Hospital, 16147 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Svahn","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Children\u2019s Hospital, 16147 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-8402","authenticated-orcid":false,"given":"Angelo","family":"Molinari","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Children\u2019s Hospital, 16147 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V2.2.185.185","article-title":"Contribution to the pathogenesis of hemophilia","volume":"2","author":"Pavlovsky","year":"1947","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/bmj.2.4799.1378","article-title":"Christmas disease: A condition previously mistaken for haemophilia","volume":"2","author":"Biggs","year":"1952","journal-title":"Br. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1958.tb03830.x","article-title":"Haemophilia and related conditions: A survey of 187 cases","volume":"4","author":"Biggs","year":"1958","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","volume":"36","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop. Scand. Suppl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mpd.2002.128115","article-title":"What factors influence the age at diagnosis of hemophilia? Results of the French hemophilia cohort","volume":"141","author":"Chambost","year":"2002","journal-title":"J. Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archpedi.1994.02170060043007","article-title":"Initial presentations of pediatric hemophiliacs","volume":"148","author":"Conway","year":"1994","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1651-2227.1990.tb11438.x","article-title":"Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases","volume":"79","author":"Ljung","year":"1990","journal-title":"Acta Paediatr. Scand."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0950-3536(96)80059-X","article-title":"The molecular basis of haemophilia A and B","volume":"9","author":"Giannelli","year":"1996","journal-title":"Baillieres. Clin. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2141.2001.02362.x","article-title":"Perinatal management of newborns with haemophilia","volume":"112","author":"Kulkarni","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00043426-199907000-00009","article-title":"Intracranial and extracranial hemorrhages in newborns with hemophilia: A review of the literature","volume":"21","author":"Kulkarni","year":"1999","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2010.08545.x","article-title":"Guideline on the management of haemophilia in the fetus and neonate","volume":"154","author":"Chalmers","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2516.2007.01492.x","article-title":"The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: Analysis of the Nationwide Inpatient Sample database","volume":"13","author":"Tarantino","year":"2007","journal-title":"Haemophilia"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lee, C.A., Berntorp, E., and Hoots, K. (2010). The neonate with Hemophilia. Textbook of Hemophilia, Wiley-Blackwell. [2010 ed.].","DOI":"10.1002\/9781444318555"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/hae.13075","article-title":"Non-genetic risk factors in haemophilia A inhibitor management\u2014The danger theory and the use of animal models","volume":"22","author":"Lovgren","year":"2016","journal-title":"Haemophilia"},{"key":"ref_18","first-page":"11","article-title":"Vaccination are not increasing the risk for inhibitor development","volume":"23","author":"Hashemi","year":"2017","journal-title":"Haemophilia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2516.2008.01695.x","article-title":"Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors\u2019 Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology","volume":"14","author":"Keeling","year":"2008","journal-title":"Haemophilia"},{"key":"ref_20","unstructured":"(2016). Masac Recommendation on Sippet (Survey of Inhibitors in Plasmaproduct-Exposed Toddlers): Results and Recommendations for Treatment Products for Previously Untreated Patients with Hemophilia A, National Hemophilia Foundation. Available online: https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/243SIPPET.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fischer, K., and Blatny, J. (2016). Do the SIPPET study results apply to the patients I treat?. Haemophilia, 8.","DOI":"10.1111\/hae.13133"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/17474086.2016.1252670","article-title":"Personalized prophylaxis in people with hemophilia A: Challenges and achievements","volume":"9","author":"Ar","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1160\/TH08-07-0462","article-title":"The next generation of anti-haemophilia factor, factor VIII. Long-lasting protection from spontaneous bleeding, are we there yet?","volume":"100","author":"Powell","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH09-04-0255","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX","volume":"102","author":"Metzner","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tiede, A., bdul-Karim, F., Carcao, M., Persson, P., Clausen, W.H., Kearney, S., Matsushita, T., Negrier, C., Oldenburg, J., and Santagostino, E. (2017). Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: Results from two phase 3 clinical trials. Haemophilia.","DOI":"10.1111\/hae.13191"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: First-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr. Scand."},{"key":"ref_31","first-page":"s116","article-title":"Advances in hemophilia and the role of current and emerging prophylaxis","volume":"22","author":"Acharya","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Abshire","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2015.10.006","article-title":"Factor VIII\/factor IX prophylaxis for severe hemophilia","volume":"53","author":"Carcao","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1160\/TH15-08-0664","article-title":"Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels","volume":"115","author":"Ljung","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12959-016-0103-3","article-title":"Aspects of prophylactic treatment of hemophilia","volume":"14","author":"Ljung","year":"2016","journal-title":"Thromb. J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Berntorp, E. (2017). If you know you will also see: Population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. J. Thromb. Haemost.","DOI":"10.1111\/jth.13682"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/hae.12375","article-title":"The burden of bleeding in haemophilia: Is one bleed too many?","volume":"20","author":"Gringeri","year":"2014","journal-title":"Haemophilia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","article-title":"New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development","volume":"16","author":"Kurnik","year":"2010","journal-title":"Haemophilia"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fischer, K., and Ljung, R. (2017). Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells Mol. Dis.","DOI":"10.1016\/j.bcmd.2017.02.004"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: A systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1160\/TH16-01-0049","article-title":"The burden of inhibitors in haemophilia patients","volume":"116","author":"Walsh","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: Communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","article-title":"A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia. A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII\/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1365-2516.2009.01999.x","article-title":"Paediatric haemophilia with inhibitors: Existing management options, treatment gaps and unmet needs","volume":"15","author":"Santagostino","year":"2009","journal-title":"Haemophilia"},{"key":"ref_45","first-page":"1","article-title":"Summary report of the First International Conference on inhibitors in haemophilia A","volume":"25","author":"Scott","year":"2016","journal-title":"Blood Transfus."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2014.07.003","article-title":"Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: Observations from the Dosing Observational Study in Hemophilia (DOSE)","volume":"17","author":"Recht","year":"2014","journal-title":"Value Health"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2516.2006.01261.x","article-title":"Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ejh.12495","article-title":"Genetic risk factors for inhibitors in haemophilia A","volume":"94","author":"Bardi","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.12602","article-title":"Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors","volume":"21","author":"Ewing","year":"2015","journal-title":"Haemophilia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2516.2009.02104.x","article-title":"FEIBA prophylaxis in haemophilia patients: A clinical update and treatment recommendations","volume":"16","author":"Perry","year":"2010","journal-title":"Haemophilia"},{"key":"ref_52","first-page":"123","article-title":"[Long-term prophylaxis in congenital haemophilia with inhibitors\u2014Experiences with rFVIIa]","volume":"27","author":"Auerswald","year":"2007","journal-title":"Hamostaseologie"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N. Eng Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: A randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1538-7836.2006.02127.x","article-title":"The international immune tolerance study: A multicenter prospective randomized trial in progress","volume":"4","author":"DiMichele","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12028","article-title":"Immune tolerance in haemophilia: The long journey to the fork in the road","volume":"159","author":"DiMichele","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: Current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia UK Haemophilia Centre Doctors Organization: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2009.02158.x","article-title":"Arteriovenous fistula as stable venous access in children with severe haemophilia","volume":"16","author":"Mancuso","year":"2010","journal-title":"Haemophilia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2516.2003.00840.x","article-title":"Central venous access devices in haemophilia","volume":"10","author":"Valentino","year":"2004","journal-title":"Haemophilia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2516.2004.00943.x","article-title":"Consensus recommendations for use of central venous access devices in haemophilia","volume":"10","author":"Ewenstein","year":"2004","journal-title":"Haemophilia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bdj.2013.1097","article-title":"Guidance on the dental management of patients with haemophilia and congenital bleeding disorders","volume":"215","author":"Anderson","year":"2013","journal-title":"Br. Dent. J."},{"key":"ref_64","unstructured":"Brewer, A., and Correa, M. (2006). Guidelines for Dental Treatment of Patients with Inherited Bleeding Disorders, World Federation of Hemophilia (WFH)."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"W336","DOI":"10.2214\/AJR.14.12501","article-title":"Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation","volume":"204","author":"Doria","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH12-11-0874","article-title":"Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)","volume":"109","author":"Martinoli","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0036-1579640","article-title":"Assessment of Hemophilic Arthropathy by Ultrasound: Where Do We Stand?","volume":"42","author":"Ambrosino","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"(2012). Children with haemophilia can play sport without excessive risk of bleeding. Nurs. Stand., 27, 14.","DOI":"10.7748\/ns.27.11.14.s20"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PEP.0000000000000296","article-title":"Sporting Activities and Quality of Life in Children With Hemophilia: An Observational Study","volume":"28","author":"Jose","year":"2016","journal-title":"Pediatr. Phys. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/hae.12912","article-title":"The impact of sport on health status, psychological well-being and physical performance of adults with haemophilia","volume":"22","author":"Von","year":"2016","journal-title":"Haemophilia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2012.13303","article-title":"Collision sports and risk of bleeding in children with hemophilia","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/hex.12083","article-title":"Self-management and skills acquisition in boys with haemophilia","volume":"18","author":"Khair","year":"2015","journal-title":"Health Expect"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0031-1286292","article-title":"Haemophilia and exercise","volume":"33","author":"Souza","year":"2012","journal-title":"Int. J. Sports Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/hae.12696","article-title":"Organized sports participation and the association with injury in paediatric patients with haemophilia","volume":"21","author":"McGee","year":"2015","journal-title":"Haemophilia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2008.01948.x","article-title":"Haemophilia care in adolescents\u2014Compliance and lifestyle issues","volume":"15","author":"Petrini","year":"2009","journal-title":"Haemophilia"},{"key":"ref_76","first-page":"e349","article-title":"Practical aspects of psychological support to the patient with haemophilia from diagnosis in infancy through childhood and adolescence","volume":"22","author":"Barbero","year":"2016","journal-title":"Haemophilia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cpp.569","article-title":"Psycho-social determinants of quality of life in children and adolescents with haemophilia-a cross-cultural approach","volume":"15","author":"Bullinger","year":"2008","journal-title":"Clin. Psychol. Psychother."},{"key":"ref_78","first-page":"871","article-title":"Mental health of children and adolescents in Germany. Results from the BELLA study within the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)","volume":"50","author":"Wille","year":"2007","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2516.2002.00642.x","article-title":"The impact of chronic disease on the family","volume":"8","author":"Goldstein","year":"2002","journal-title":"Haemophilia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/hae.12379","article-title":"Understanding the experience of caring for children with haemophilia: Cross-sectional study of caregivers in the United States","volume":"20","author":"DeKoven","year":"2014","journal-title":"Haemophilia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2516.2007.01494.x","article-title":"Parents of children with haemophilia\u2014A transforming experience","volume":"13","author":"Beeton","year":"2007","journal-title":"Haemophilia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2516.2008.01803.x","article-title":"Quality of life, psychosocial strains and coping in parents of children with haemophilia","volume":"14","author":"Wiedebusch","year":"2008","journal-title":"Haemophilia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2516.2006.01428.x","article-title":"Psychological aspects and coping styles of parents with Haemophilic child undergoing a programme of counselling and psychological support","volume":"13","author":"Bottos","year":"2007","journal-title":"Haemophilia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","article-title":"A survey of adherence to haemophilia therapy in six European countries: Results and recommendations","volume":"14","author":"De","year":"2008","journal-title":"Haemophilia"},{"key":"ref_85","first-page":"195","article-title":"Building resilience in families with pediatric chronic diseases","volume":"1","author":"Grau","year":"2013","journal-title":"Revista Espa\u00f1ola de Discapacidad"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/5\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:36:27Z","timestamp":1760207787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/5\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["jcm6050054"],"URL":"https:\/\/doi.org\/10.3390\/jcm6050054","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]}}}